Biswas, Subir
Anadon, Carmen M. http://orcid.org/0000-0002-8851-4545
Conejo-Garcia, Jose R. http://orcid.org/0000-0001-6431-4074
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA278907, R01CA124515, R01CA178687)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Cancer Research Institute (CLIP award)
Article History
Received: 22 November 2023
Revised: 29 November 2023
Accepted: 1 December 2023
First Online: 13 December 2023
Competing interests
: JRCG has stock options in Compass Therapeutics, Anixa Biosciences and Alloy Therapeutics; has sponsored research with Anixa Biosciences; receives an honorarium from Alloy Therapeutics; and intellectual property with Compass Therapeutics and Anixa Biosciences; and is co-founder of Cellepus Therapeutics; all outside the submitted work. JRCG, SB and CMA have filed a patent application for intracellular targeting of oncodrivers using modified IgG.